With fewer depression symptoms, you may begin to

FEEL LIKE YOURSELF AGAIN.



SPRAVATO® is the only FDA-approved nasal spray for adults with treatment-resistant depression. It can be taken with or without an oral antidepressant.

Spravato® (esketamine) CIII
28 mg nasal spray

Visit SPRAVATO.com ›

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about SPRAVATO®?

SPRAVATO® can cause serious side effects, including:

- **Sedation, dissociation, and respiratory depression.** SPRAVATO® may cause sleepiness (sedation), fainting, dizziness, spinning sensation, anxiety, or feeling disconnected from yourself, your thoughts, feelings, space and time (dissociation), breathing problems (respiratory depression and respiratory arrest)
  - Tell your healthcare provider right away if you feel like you cannot stay awake or if you feel like you are going to pass out.
  - Your healthcare provider must monitor you for serious side effects for at least 2 hours after taking SPRAVATO®. Your healthcare provider will decide when you are ready to leave the healthcare setting.

Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

IMPORTANT SAFETY INFORMATION (continued)

- **Abuse and misuse.** There is a risk for abuse and misuse with SPRAVATO®, which may lead to physical and psychological dependence. Your healthcare provider should check you for signs of abuse, misuse, and dependence before and during treatment.
  - Tell your healthcare provider if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs.
  - Your healthcare provider can tell you more about the differences between physical and psychological dependence in drug addiction.
- **SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS).** Because of the risks for sedation, dissociation, respiratory depression, and abuse and misuse, SPRAVATO® is only available through a restricted program called the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program. SPRAVATO® can only be administered at healthcare settings certified in the SPRAVATO® REMS Program. Patients treated in outpatient healthcare settings (such as medical offices and clinics) must be enrolled in the program.
- **Increased risk of suicidal thoughts and actions.** Antidepressant medicines may increase suicidal thoughts and actions in some people 24 years of age and younger, **especially within the first few months of treatment or when the dose is changed. SPRAVATO® is not for use in children.**
  - Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a higher risk of having suicidal thoughts or actions. These include people who have (or have a family history of) depression or a history of suicidal thoughts or actions.
- **How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?**
  - Pay close attention to any changes, especially sudden changes, in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions.
  - Tell your healthcare provider right away if you have any new or sudden changes in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions.
  - Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms.
- **Tell your healthcare provider or get emergency help right away if you or your family member have any of the following symptoms, especially if they are new, worse, or worry you:**
  - thoughts about suicide or dying
  - new or worse depression
  - feeling very agitated or restless
  - trouble sleeping (insomnia)
  - acting aggressive, being angry or violent
  - an extreme increase in activity and talking (mania)
  - suicide attempts
  - new or worse anxiety
  - panic attacks
  - new or worse irritability
  - acting on dangerous impulses
  - other unusual changes in behavior or mood

What is SPRAVATO® (esketamine) CIII nasal spray?

SPRAVATO® is a prescription medicine used:

- with or without an antidepressant taken by mouth, to treat adults with treatment-resistant depression (TRD)
- with an antidepressant taken by mouth, to treat depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions

SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe or effective as an anesthetic medicine.

It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.

It is not known if SPRAVATO® is safe and effective in children.

Please see Important Safety Information on pages 17-21 and see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

Spravato® (esketamine) CIII
28 mg nasal spray

For many people, oral antidepressants may not provide enough symptom relief

Major depressive disorder (MDD), also known as clinical depression, is one of the most common mental health disorders in the United States.



Clinical depression affects more than 21 million adults.



According to a study, 1 in 3 people did not experience a reduction in their depression symptoms when taking oral antidepressants alone.

If you have taken 2 or more oral antidepressants and still experience symptoms of depression, you may have **treatment-resistant depression (TRD)**.

If you have treatment-resistant depression, you have options.

Please see Important Safety Information on pages 17-21 and see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

Spravato® (esketamine) CIII
28 mg nasal spray

SPRAVATO® works differently than traditional antidepressants

SPRAVATO® is not a pill you need to take every day. It is **the only FDA-approved nasal spray for adults with treatment-resistant depression** that can be taken with or without an oral antidepressant.



Glutamate*

Unlike traditional antidepressants that work on serotonin, norepinephrine, and dopamine, SPRAVATO® acts on **glutamate**, a chemical messenger in the brain that is thought to regulate depression.

The role of glutamate in depression and the exact way SPRAVATO® works are unknown.

Did you know 9 out of 10 people with commercial insurance are covered for SPRAVATO®?†

Learn more about coverage ›

*A chemical messenger. SPRAVATO® is an NMDA receptor antagonist believed to work on glutamate.

†TRD data only. Managed Markets Insights and Technology, LLC™, a trademark of MMIT, as of September 2024. Collected as of September 2024 and may change. This percentage may not represent 100% of formulary lives due to data limitations.

NMDA=N-methyl-D-aspartate.

Please see Important Safety Information on pages 17-21 and see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

Spravato® (esketamine) CIII
28 mg nasal spray

SPRAVATO® can provide rapid relief with proven results

Patients were given either SPRAVATO® alone or a placebo nasal spray alone in a randomized clinical study. The study showed:

Rapid and superior reduction in depression symptoms at **~4 weeks and 24 hours** for patients using SPRAVATO® alone compared with those who received a placebo nasal spray alone.

Helps reduce depression symptoms as early as **one day**.

Watch real stories from real people ›

Please see Important Safety Information on pages 17-21 and see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

Spravato® (esketamine) CIII
28 mg nasal spray

SPRAVATO®, in combination with an oral antidepressant, is the only FDA-approved medication for treatment-resistant depression that has long-term safety and results data out to 5 years.



Please see Important Safety Information on pages 17-21 and see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

Spravato® (esketamine) CIII
28 mg nasal spray

Possible side effects

SPRAVATO® may cause serious side effects, including sleepiness (sedation), fainting, dizziness, spinning sensation, anxiety, or feeling disconnected from yourself, your thoughts, feelings, space and time (dissociation), and breathing problems (respiratory depression and respiratory arrest).

The most common side effects are

- feeling disconnected from yourself, your thoughts, feelings and things around you
- dizziness
- nausea
- feeling sleepy
- spinning sensation
- decreased feeling of sensitivity (numbness)
- feeling anxious
- lack of energy
- increased blood pressure
- vomiting
- feeling drunk
- headache
- feeling very happy or excited

If these common side effects occur, they usually happen right after taking SPRAVATO® and go away the same day.

Please see Important Safety Information on pages 17-21 and see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

Spravato® (esketamine) CIII
28 mg nasal spray

What to expect

SPRAVATO® is taken in healthcare offices that are certified to administer SPRAVATO®. This could be at a **different location** than your usual healthcare provider's office. If your healthcare provider determines that SPRAVATO® is right for you but does not offer SPRAVATO® you can work with your provider or click here to find a SPRAVATO® healthcare office near you.

SPRAVATO® can be **taken with or without another antidepressant**. So, if you are already on another treatment for treatment-resistant depression, don't worry—talk to your healthcare provider about what makes the most sense for you.

For the first month, you'll take SPRAVATO® **twice per week**, and then **once per week** for the second month. After the first month and throughout treatment, you and your healthcare provider will determine if SPRAVATO® should be continued and how often.



Please see Important Safety Information on pages 17-21 and see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

Spravato® (esketamine) CIII
28 mg nasal spray

Your consultation

Starting on SPRAVATO® treatment **begins with a consultation** between you and a healthcare provider. You may start treatment as soon as your second visit.

The provider's office will:



Receive your medical information from your usual healthcare provider.



Conduct an assessment to confirm whether SPRAVATO® is right for you.



Check to see how SPRAVATO® is covered by your insurance or if you are eligible for affordability support programs. SPRAVATO® is covered by most insurance plans.*



Write you a prescription if you and your doctor have decided that SPRAVATO® is right for you. The prescription may be sent to a specialty pharmacy. If so, the pharmacy will call you to review and confirm your coverage before shipping SPRAVATO® to your provider's office.

Tip: The pharmacy may call from an unknown number, so be sure to answer the phone.

*TRD data only. Managed Markets Insights and Technology, LLC™, a trademark of MMIT, as of September 2024. Collected as of September 2024 and may change. This percentage may not represent 100% of formulary lives due to data limitations.

Please see Important Safety Information on pages 17-21 and see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

Spravato® (esketamine) CIII
28 mg nasal spray

Treatment days



You will administer SPRAVATO® nasal spray yourself under the supervision of a healthcare provider at a certified SPRAVATO® office.



After you administer SPRAVATO®, there will be an observation period of at least 2 hours, during which you will rest comfortably while a healthcare provider monitors you for possible side effects.

Because of possible side effects affecting mental alertness and motor coordination, you won't be able to drive, operate machinery, or do anything where you need to be completely alert until the next day, following a restful sleep.



Please see Important Safety Information on pages 17-21 and see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

Spravato® (esketamine) CIII
28 mg nasal spray

Treatment tips



Avoid eating 2 hours before, and drinking liquids 30 minutes before, the treatment session. Some patients taking SPRAVATO® may experience nausea.



If you take a nasal corticosteroid or nasal decongestant medicine, take these medicines at least 1 hour before taking SPRAVATO.®



Many people spend the observation time relaxing, listening to music, reading, or resting.



Check with your insurance to see if they cover transportation to and/or from your appointment. Your provider's office may also be able to help you arrange a ride.

Your usual healthcare provider will continue to be involved with your care during treatment, even if you don't receive SPRAVATO® at the same office.


Please see Important Safety Information on pages 17-21 and see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

Spravato® (esketamine) CIII
28 mg nasal spray

The right treatment schedule for you

Throughout treatment, you and your healthcare provider will work together to determine if treatment should be continued and how often you should take it.

You will take SPRAVATO® twice a week for four weeks, and then once a week during the second month. After that, some people continue treatment once a week, while others might switch to every other week.



Please see Important Safety Information on pages 17-21 and see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

Spravato® (esketamine) CIII
28 mg nasal spray

Continuing SPRAVATO® with an oral antidepressant treatment could help you reduce the risk of a return of depression symptoms

SPRAVATO® was studied to see if the effect of treatment was maintained over time. The trial compared people who stayed on SPRAVATO® and an oral antidepressant to people on a placebo nasal spray and oral antidepressant, long-term.



The study showed:

People who stayed on SPRAVATO® were less likely to experience a return of depression symptoms compared with people who stopped treatment.

The most common side effects that occurred in >15% of patients on SPRAVATO® include the following:

Headache; dizziness; nausea; feeling disconnected from yourself, your thoughts, feelings, space and time; somnolence; nasal congestion, sore throat and runny nose; altered taste; back pain; spinning sensation; anxiety; vomiting; joint pain; diarrhea.

Please see Important Safety Information on pages 17-21 and see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

Spravato® (esketamine) CIII
28 mg nasal spray

Once you and your doctor have decided that SPRAVATO® is right for you

Spravato withMe | Spravato® (esketamine) C III 28 mg nasal spray

Have commercial or private insurance? You have 2 ways to save.

Take advantage of both of the programs below and maximize your savings

Pay as little as $10 per treatment for your SPRAVATO® medicine

SPRAVATO withMe Savings Program

Treatment may include up to three devices administered on the same day. There are quantity limits and a maximum program benefit per calendar year. Offer subject to change or end without notice. Program does not cover the cost of treatment observation. Participate without sharing your income information. See program requirements at **Spravato.com/SavingsRequirements**

Pay $0 after rebate for observation of each treatment

SPRAVATO withMe Observation Rebate Program

There is a limit to savings each year. Offer subject to change or end without notice. Not valid for residents of MA, MN, or RI. Participate without sharing your income information. See program requirements at **Spravato.com/Observation**

The support and resources provided by SPRAVATO withMe are not intended to provide medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment.

Please see Important Safety Information on pages 17-21 and see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.



Three ways to sign up for SPRAVATO withMe:

SpravatowithMePatientAuth.com

Call 1-844-4S-WITHME (1-844-479-4846) and press option 2

Monday – Friday, 8:00 AM – 8:00 PM ET

Talk to your doctor about enrolling in SPRAVATO withMe ›

Please see Important Safety Information on pages 17-21 and see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

Spravato® (esketamine) CIII
28 mg nasal spray

SPRAVATO® can help with depression symptoms in adults with MDD with suicidal thoughts or actions (MDSI)



In clinical studies of adults with MDSI, those who took SPRAVATO® and an oral antidepressant experienced a greater reduction of depression symptoms at 24 hours compared with those who received a placebo plus an oral antidepressant.*

Help is available 24/7. If you're struggling with suicidal thoughts, call 988 Suicide & Crisis Lifeline.

Limitations of Use

It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.

SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe or effective as an anesthetic medicine.

It is not known if SPRAVATO® is safe and effective in children.

*Based on an overall score on a standardized rating scale.

Please see Important Safety Information on pages 17-21 and see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

Spravato® (esketamine) CIII
28 mg nasal spray

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about SPRAVATO®?

SPRAVATO® can cause serious side effects, including:

- **Sedation, dissociation, and respiratory depression**. SPRAVATO® may cause sleepiness (sedation), fainting, dizziness, spinning sensation, anxiety, or feeling disconnected from yourself, your thoughts, feelings, space and time (dissociation), breathing problems (respiratory depression and respiratory arrest)
  - Tell your healthcare provider right away if you feel like you cannot stay awake or if you feel like you are going to pass out.
  - Your healthcare provider must monitor you for serious side effects for at least 2 hours after taking SPRAVATO®. Your healthcare provider will decide when you are ready to leave the healthcare setting.
- **Abuse and misuse**. There is a risk for abuse and misuse with SPRAVATO®, which may lead to physical and psychological dependence. Your healthcare provider should check you for signs of abuse, misuse, and dependence before and during treatment.
  - Tell your healthcare provider if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs.
  - Your healthcare provider can tell you more about the differences between physical and psychological dependence in drug addiction.
- **SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS)**. Because of the risks for sedation, dissociation, respiratory depression, and abuse and misuse, SPRAVATO® is only available through a restricted program called the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program. SPRAVATO® can only be administered at healthcare settings certified in the SPRAVATO® REMS Program. Patients treated in outpatient healthcare settings (such as medical offices and clinics) must be enrolled in the program.

(continued on next page)

Please see Important Safety Information on pages 17-21 and see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

Spravato® (esketamine) CIII
28 mg nasal spray

IMPORTANT SAFETY INFORMATION (continued)

- **Increased risk of suicidal thoughts and actions**. Antidepressant medicines may increase suicidal thoughts and actions in some people 24 years of age and younger, **especially within the first few months of treatment or when the dose is changed. SPRAVATO® is not for use in children.**
  - Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a higher risk of having suicidal thoughts or actions. These include people who have (or have a family history of) depression or a history of suicidal thoughts or actions.
- **How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?**
  - Pay close attention to any changes, especially sudden changes, in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions.
  - Tell your healthcare provider right away if you have any new or sudden changes in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions.
  - Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms.
- **Tell your healthcare provider or get emergency help right away if you or your family member have any of the following symptoms, especially if they are new, worse, or worry you:**
  - thoughts about suicide or dying
  - new or worse depression
  - feeling very agitated or restless
  - trouble sleeping (insomnia)
  - acting aggressive, being angry or violent
  - an extreme increase in activity and talking (mania)
  - suicide attempts
  - new or worse anxiety
  - panic attacks
  - new or worse irritability
  - acting on dangerous impulses
  - other unusual changes in behavior or mood

Do not take SPRAVATO® if you:

- have blood vessel (aneurysmal vascular) disease (including in the brain, chest, abdominal aorta, arms and legs)
- have an abnormal connection between your veins and arteries (arteriovenous malformation)

(continued on next page)

Please see Important Safety Information on pages 17-21 and see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

Spravato® (esketamine) CIII
28 mg nasal spray

IMPORTANT SAFETY INFORMATION (continued)

- have a history of bleeding in the brain
- are allergic to esketamine, ketamine, or any of the other ingredients in SPRAVATO®.

If you are not sure if you have any of the above conditions, talk to your healthcare provider before taking SPRAVATO®.

Before you take SPRAVATO®, tell your healthcare provider about all of your medical conditions, including if you:

- have heart or brain problems, including:
  - high blood pressure (hypertension)
  - slow or fast heartbeats that cause shortness of breath, chest pain, lightheadedness, or fainting
  - history of heart attack
  - history of stroke
  - heart valve disease or heart failure
  - history of brain injury or any condition where there is increased pressure in the brain
- have liver problems
- have ever had a condition called "psychosis" (see, feel, or hear things that are not there, or believe in things that are not true).
- are pregnant or plan to become pregnant. SPRAVATO® may harm your unborn baby. You should not take SPRAVATO® if you are pregnant.
  - Tell your healthcare provider right away if you become pregnant during treatment with SPRAVATO®.
  - If you are able to become pregnant, talk to your healthcare provider about methods to prevent pregnancy during treatment with SPRAVATO®.
  - There is a pregnancy registry for women who are exposed to SPRAVATO® during pregnancy. The purpose of the registry is to collect information about the health of women exposed to SPRAVATO® and their baby. If you become pregnant during treatment with SPRAVATO®, talk to your healthcare provider about registering with the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or online at https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/antidepressants/.

(continued on next page)

Please see Important Safety Information on pages 17-21 and see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

Spravato® (esketamine) CIII
28 mg nasal spray

IMPORTANT SAFETY INFORMATION (continued)

- are breastfeeding or plan to breastfeed. SPRAVATO® passes into your breast milk. You should not breastfeed during treatment with SPRAVATO®.

Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Taking SPRAVATO® with certain medicine may cause side effects.

Especially tell your healthcare provider if you take central nervous system (CNS) depressants, psychostimulants, or monoamine oxidase inhibitors (MAOIs) medicine. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.

How will I take SPRAVATO®?

- You will take SPRAVATO® nasal spray yourself, under the supervision of a healthcare provider in a healthcare setting. Your healthcare provider will show you how to use the SPRAVATO® nasal spray device.
- Your healthcare provider will tell you how much SPRAVATO® you will take and when you will take it.
- Follow your SPRAVATO® treatment schedule exactly as your healthcare provider tells you to.
- During and after each use of the SPRAVATO® nasal spray device, you will be checked by a healthcare provider who will decide when you are ready to leave the healthcare setting.
- You will need to plan for a caregiver or family member to drive you home after taking SPRAVATO®.
- If you miss a SPRAVATO® treatment, your healthcare provider may change your dose and treatment schedule.
- Some people taking SPRAVATO® get nausea and vomiting. You should not eat for at least 2 hours before taking SPRAVATO® and not drink liquids at least 30 minutes before taking SPRAVATO®.
- If you take a nasal corticosteroid or nasal decongestant medicine take these medicines at least 1 hour before taking SPRAVATO®.

What should I avoid while taking SPRAVATO®?

Do not drive, operate machinery, or do anything where you need to be completely alert after taking SPRAVATO®. Do not take part in these activities until the next day following a restful sleep. See **"What is the most important information I should know about SPRAVATO®?"**

(continued on next page)

Please see Important Safety Information on pages 17-21 and see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

Spravato® (esketamine) C III
28 mg nasal spray

IMPORTANT SAFETY INFORMATION (continued)

What are the possible side effects of SPRAVATO®?

SPRAVATO® may cause serious side effects including:

See **"What is the most important information I should know about SPRAVATO®?"**

Increased blood pressure. SPRAVATO® can cause a temporary increase in your blood pressure that may last for about 4 hours after taking a dose. Your healthcare provider will check your blood pressure before taking SPRAVATO® and for at least 2 hours after you take SPRAVATO®. Tell your healthcare provider right away if you get chest pain, shortness of breath, sudden severe headache, change in vision, or seizures after taking SPRAVATO®.

Problems with thinking clearly. Tell your healthcare provider if you have problems thinking or remembering.

Bladder problems. Tell your healthcare provider if you develop trouble urinating, such as a frequent or urgent need to urinate, pain when urinating, or urinating frequently at night.

The most common side effects of SPRAVATO® include:

- feeling disconnected from yourself, your thoughts, feelings and things around you
- dizziness
- nausea
- feeling sleepy
- spinning sensation
- decreased feeling of sensitivity (numbness)
- feeling anxious
- lack of energy
- increased blood pressure
- vomiting
- feeling drunk
- headache
- feeling very happy or excited

If these common side effects occur, they usually happen right after taking SPRAVATO® and go away the same day.

These are not all the possible side effects of SPRAVATO®.

Call your doctor for medical advice about side effects. You may report side effects to Johnson & Johnson at 1-800-526-7736, or to the FDA at 1-800-FDA-1088.

Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

cp-170363v4


Spravato®
(esketamine) C III
28 mg nasal spray
If you are looking for a certified SPRAVATO® provider, click below.
Locate a certified SPRAVATO® provider near you ›
Please see Important Safety Information on pages 17-21 and see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.
© Johnson & Johnson and its affiliates 2026 03/26 cp-437461v4